{"entity":{"id":"nct04543955","kind":"trial","name":"Telotristat With Lutathera in Neuroendocrine Tumors","aka":[],"tldr":"A phase 2 trial of Telotristat ethyl in Neuroendocrine tumours, run by Lowell Anthony, MD, recorded as terminated on the registry.","summary":"Telotristat With Lutathera in Neuroendocrine Tumors is a phase 2 interventional study registered as NCT04543955 by Lowell Anthony, MD, with 1 participants recorded, started 2021-09-13 and due to reach its primary completion in 2022-06-03. Interventions recorded: Telotristat (Low-Dose), Telotristat (High-Dose). Conditions recorded: Neuroendocrine Tumors.\n\nLinked to the drug Telotristat ethyl because the registry names it among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04543955","url":"https://clinicaltrials.gov/study/NCT04543955"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["telotristat-ethyl"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04543955","phase":"2","setting":"Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors","sponsor":"Lowell Anthony, MD","enrolled":1,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04543955/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"drug":[{"id":"telotristat-ethyl","kind":"drug","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/"}]}}